{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:00:05Z","timestamp":1761102005107},"reference-count":25,"publisher":"Canadian Science Publishing","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p> Protein kinase C variants (PKCs) have been involved in the control of airway smooth muscle (ASM) tone, and abnormalities in PKC-dependent signaling have been associated with respiratory diseases such as asthma. In this study, the role of atypical PKC\u03b6 in airway hyperresponsiveness was investigated, using an in-vitro model of TNF\u03b1-treated human bronchi and an in vivo guinea pig model of chronic asthma. Our results demonstrated that PKC\u03b6-specific inhibition produced a significant increase in isoproterenol sensitivity in TNF\u03b1-treated bronchi and ovalbumin (OVA)-sensitized guinea pig bronchi. The role of epoxy-eicosanoids, known to exert anti-inflammatory effects in lung, on PKC\u03b6 expression and activity in these models was evaluated. An enhanced PKC\u03b6 protein expression was delineated in TNF\u03b1-treated bronchi when compared with control (untreated) and epoxy-eicosanoid-treated bronchi. Measurements of Ca<jats:sup>2+<\/jats:sup> sensitivity, performed in TNF\u03b1-treated bronchi, demonstrated that treatment with myristoylated (Myr) PKC\u03b6 peptide inhibitor resulted in significant reductions of pCa-induced tension. Epoxy-eicosanoid treatments had similar effects on Ca<jats:sup>2+<\/jats:sup> sensitivity in TNF\u03b1-treated bronchi. In control and epoxy-eicosanoid-treated bronchi, the phosphorylated forms of p38MAPK and CPI-17 were significantly decreased compared with the TNF\u03b1-treated bronchi. An enhanced expression of PKC\u03b6 was ascertained in our in-vivo model of allergic asthma. Hence an increased Ca<jats:sup>2+<\/jats:sup> sensitivity could be explained by the phosphorylation of p38-MAPK, which in turn leads to phosphorylation and activation of the CPI-17 regulatory protein. This process was reversed upon treatment with the Myr-PKC\u03b6-peptide inhibitor. The present data provide relevant evidence regarding the role of PKC\u03b6 in human and rodent models of airways inflammation. <\/jats:p>","DOI":"10.1139\/y11-117","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T11:55:13Z","timestamp":1329220513000},"page":"261-269","source":"Crossref","is-referenced-by-count":12,"title":["Bronchial inflammation induced PKC<sub>\u03b6<\/sub> over-expression: involvement in mechanical properties of airway smooth muscle"],"prefix":"10.1139","volume":"90","author":[{"given":"Caroline","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada."},{"name":"SCF Pharma, 235 route du Fleuve Ouest, Ste-Luce, QC G0K 1P0, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Fortin","sequence":"additional","affiliation":[{"name":"SCF Pharma, 235 route du Fleuve Ouest, Ste-Luce, QC G0K 1P0, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","reference":[{"key":"refg1\/ref1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31215"},{"key":"refg2\/ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.04.029"},{"issue":"3","key":"refg3\/ref3","first-page":"L506","volume":"276","author":"Carlin S.","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"2","key":"refg4\/ref4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4049\/jimmunol.166.2.1206","volume":"166","author":"Dang P.M.","year":"2001","journal-title":"J. Immunol."},{"key":"refg5\/ref5","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3510095"},{"issue":"4","key":"refg6\/ref6","first-page":"561","volume":"23","author":"Do J.S.","year":"2009","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"refg7\/ref7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1165\/ajrcmb.13.3.7654381","volume":"13","author":"Donnelly R.","year":"1995","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"refg8\/ref8","first-page":"280","volume":"38","author":"Fatma S.","year":"2001","journal-title":"Indian J. Biochem. Biophys."},{"issue":"1","key":"refg9\/ref9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/jphysiol.1997.sp022002","volume":"500","author":"Gailly P.","year":"1997","journal-title":"J. Physiol."},{"key":"refg10\/ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.05.012"},{"key":"refg11\/ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15369-X"},{"key":"refg12\/ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804073"},{"key":"refg13\/ref13","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00214.2007"},{"key":"refg14\/ref14","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0808492"},{"issue":"4","key":"refg15\/ref15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI18193","volume":"112","author":"McGraw D.W.","year":"2003","journal-title":"J. Clin. Invest."},{"key":"refg16\/ref16","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2007-0232OC"},{"key":"refg17\/ref17","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0155OC"},{"key":"refg18\/ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.05.008"},{"key":"refg19\/ref19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200708-1217PP"},{"key":"refg20\/ref20","doi-asserted-by":"publisher","DOI":"10.2741\/3385"},{"key":"refg21\/ref21","doi-asserted-by":"publisher","DOI":"10.1540\/jsmr.45.55"},{"key":"refg22\/ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(95)02062-N"},{"issue":"4","key":"refg23\/ref23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1476-5381.1996.tb15733.x","volume":"119","author":"Sipma H.","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"refg24\/ref24","first-page":"209","volume":"365","author":"Walsh M.P.","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"refg25\/ref25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.041418"}],"container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/full-xml\/10.1139\/y11-117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/y11-117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T05:31:13Z","timestamp":1578288673000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/y11-117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1139\/y11-117"],"URL":"https:\/\/doi.org\/10.1139\/y11-117","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}